Quick Read
Johnson & Johnson (JNJ) reported Q1 revenue of $24.06B, up 9.9% year over year, with adjusted EPS of $2.70 beating consensus for the fourth consecutive quarter, while oncology drugs CARVYKTI jumped 62.1% to $597M and RYBREVANT surged 82.7%, offsetting a 59.7% decline in STELARA from biosimilar competition.
Johnson & Johnson’s oncology pipeline strength and planned separation of its Orthopaedics business are creating a path to double-digit growth by decade-end, offsetting legacy drug erosion and supporting a 90% confidence buy rating with a $252.01 price target implying 9.37% upside.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Johnson & Johnson wasn’t one of them. Get them here FREE.
Johnson & Johnson (NYSE:JNJ) closed the most recent session at $230.42, up 2.58% on the week as buyers rotated back into defensive healthcare names. Our 24/7 Wall St. price target for Johnson & Johnson is $252.01 over the next 12 months, implying 9.37% upside. The recommendation is buy, and our confidence level is 90%, the high end of our scale.
24/7 Wall St. Price Target Summary
Metric
Value
Current Price
$230.42
24/7 Wall St. Price Target
$252.01
Upside
9.37%
Recommendation
BUY
Confidence Level
90%
A Defensive Compounder Riding Oncology Strength
JNJ has been one of the strongest performers in large-cap pharma over the past year, rising 59.53% over twelve months and 11.93% year to date. The stock pulled back 3.17% over the past month after the Q1 earnings report, but the 14-day RSI has rebounded from oversold territory to 51.98, signaling renewed buying interest.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Johnson & Johnson wasn’t one of them. Get them here FREE.
Q1 2026 was a clean beat. Revenue of $24.06 billion grew 9.9% year over year, and adjusted EPS of $2.70 extended the consensus beat streak to four consecutive quarters. Innovative Medicine grew 11.2% with DARZALEX at $3.96 billion and TREMFYA up 68.3%, more than absorbing a 59.7% STELARA decline…
..
